Skip to main content
English
Català
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
20 March 2017
Oryzon to Present at the Sachs Associates 2nd Annual Neuroscience BioPartnering & Investment Forum
15 March 2017
ORYZON to Present at the 11th Annual BIO-Europe Spring International Partnering Conference
27 February 2017
ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017
24 February 2017
ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016
20 February 2017
ORYZON to present ORY-2001 new preclinical data of therapeutic activity at ACTRIMS-2017 in Orlando, Fl. USA
6 February 2017
Oryzon Genomics to Present at the 19th Annual BIO CEO & Investor Conference 2017
3 February 2017
Oryzon received Best Business Practices Award for Innovation
30 January 2017
ORYZON to outline development of Lysine Specific Demethylase Inhibitors for Oncological and Neurodegenerative Diseases at Keystone Symposia on Epigenetics and Human Disease
25 January 2017
ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria
16 January 2017
ORYZON Announces Expansion of its Scientific Advisory Board
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »